Manufacturer				Pack
Name	NDC	Name of Prescription Drug	Strength	Size/Volume
Apotex Corp.	60505-4532-02	LENALIDOMIDE CAP 2.5MG 28 BTL	2.5 mg	Bottle
Apotex Corp.	60505-4536-02	LENALIDOMIDE CAP 20MG 21 BTL	20 mg	Bottle
Apotex Corp.	60505-6228-00	BENDAMUSTINE INJ 100MG/4ML VIAL	100 mg	Vial

Commercial Launch Date	A description of the marketing and pricing plans used in the launch of the new drug	Estimated volume of patients who may be prescribed drug	Breakthrough therapy designation?  (Y/N)
4/25/2023	Upon information and belief, Apotex did not engag	11065	N
4/25/2023	Upon information and belief, Apotex did not engag	11065	N
4/26/2023	Upon information and belief, Apotex did not engag	30	N

Date and price of acquisition if the drug was not developed by the manufacturer else N/A

N/A	
N/A	
N/A	